Patents by Inventor Christian Scholz

Christian Scholz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11404471
    Abstract: An optoelectronic semiconductor component may have a semiconductor body comprising a first region of an n-type conductivity, a second region of a p-type conductivity, an active region capable of generating electromagnetic radiation, a marker layer, a plurality of emission regions and a plurality of recesses. The active region is disposed between the first region and the second region in a plane parallel to the main extension plane of the semiconductor body. The recesses delimit the emission regions in lateral direction. Starting from the side of the first region facing away from the active region, the recesses extend transversely to the main plane of the semiconductor body in the direction of the second region and adjoin the marker layer or penetrate the marker layer completely. The recesses are formed only in the first region or the recesses extend into the second region and completely penetrate the active region.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: August 2, 2022
    Assignee: OSRAM OLED GMBH
    Inventors: Christian Mueller, Dominik Scholz, Joachim Hertkorn
  • Publication number: 20220220158
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ?-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 14, 2022
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11319351
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11312750
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Publication number: 20210349090
    Abstract: The present description relates to a Corona antigen having a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits having the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using the Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 11, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
  • Publication number: 20210333277
    Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 28, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
  • Patent number: 10647765
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 12, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
  • Patent number: 10626177
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Publication number: 20200048313
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Publication number: 20200048312
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Publication number: 20200033342
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 30, 2020
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Publication number: 20190367601
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 5, 2019
    Inventors: Herbert ANDRES, David CASAGOLDA VALLRIBERA, Hartmut DUEFEL, Michael GERG, Christian SCHOLZ, Michael SCHRAEML
  • Patent number: 10466242
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Patent number: 10364290
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: July 30, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 10323107
    Abstract: Unsaturated compounds of formula (I): wherein: R1, R2, and R3 are each independently H or CH3; R4 is a linear or branched C1-C30-alkylene; R5 and R6 are each independently H, C1-C20-alkyl, C3-C15-cycloalkyl, aryl, —CH2—O—C1-C20-alkyl, or —CH2—O—C2-C20-alkenyl, where R5 and R6 may together form a C3-C6-alkylene; R7 is independently H,C1-C4-alkyl, or where R8 is C1-C22-alkyl or C2-C22-alkenyl; and n is an integer from 2 to 200. Mixtures and polymers including the unsaturated compounds of formula (I). A method for preparing polymers by free-radical polymerization of monomers including the unsaturated compounds of formula (I). A process for preparing polymers including polymer-analogous reactions. And polymers including compounds (I) as cement additives, grinding aids, hydraulic binder additives, concrete plasticizers, reactive plasticizers for preparing plastics, rubber, or latex, associative thickeners and antioxidants, or for preparing polyether siloxanes.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 18, 2019
    Assignee: BASF SE
    Inventors: Sophie Maitro-Vogel, Martin Ernst, Christian Schade, Pavel Tuzina, Hoang Trang Tran-Thien, Eva-Maria Reis-Walther, Natalia Shabelina, Nina Susanne Hillesheim, Christian Scholz
  • Patent number: 10301383
    Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: May 28, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraemi
  • Patent number: 10197559
    Abstract: The invention concerns a fusion polypeptide including several molecules of folding helper polypeptides, including one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to the fusion polypeptide. The invention further concerns an immunoassay and the use of the fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising the fusion polypeptide.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: February 5, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Hartmut Duefel, Alexander Riedel, Peter Schaarschmidt, Urban Schmitt, Christian Scholz
  • Publication number: 20180305634
    Abstract: [Problem] Provided is an operating oil for shock absorber in which influences against rubber materials are controlled. [Solution] An operating oil coming into contact with a rubber material, the operating oil containing a polyalkylene glycol and at least one base oil selected from a fatty acid diester, a poly-alfa-olefin, and a lubricating oil classified as GIII in American Petroleum Institute (API). [Effect] According to the operating oil, in view of the fact that swelling properties of a rubber material, such as a seal material, etc., are reduced, conventionally used rubber materials can be used without being changed.
    Type: Application
    Filed: March 28, 2016
    Publication date: October 25, 2018
    Applicant: KYB Corporation
    Inventors: Christian Scholz, Yoshihiro Ito, Shinji Kato
  • Patent number: 10094828
    Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 9, 2018
    Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20180118837
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: August 3, 2017
    Publication date: May 3, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml